NO311783B1 - Transdermalt terapeutisk system for frigjöring av 17-<beta>- östradiol og fremgangsmåte for fremstilling derav - Google Patents
Transdermalt terapeutisk system for frigjöring av 17-<beta>- östradiol og fremgangsmåte for fremstilling derav Download PDFInfo
- Publication number
- NO311783B1 NO311783B1 NO19951765A NO951765A NO311783B1 NO 311783 B1 NO311783 B1 NO 311783B1 NO 19951765 A NO19951765 A NO 19951765A NO 951765 A NO951765 A NO 951765A NO 311783 B1 NO311783 B1 NO 311783B1
- Authority
- NO
- Norway
- Prior art keywords
- estradiol
- relative humidity
- therapeutic system
- transdermal therapeutic
- equilibrium
- Prior art date
Links
- 229960005309 estradiol Drugs 0.000 title claims abstract description 24
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 15
- 229930182833 estradiol Natural products 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 title claims description 5
- 239000010410 layer Substances 0.000 claims abstract description 28
- 239000013543 active substance Substances 0.000 claims abstract description 19
- 239000011159 matrix material Substances 0.000 claims abstract description 18
- 239000012790 adhesive layer Substances 0.000 claims abstract description 15
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims abstract description 14
- 239000000463 material Substances 0.000 claims abstract description 10
- 239000000853 adhesive Substances 0.000 claims abstract description 5
- 230000001070 adhesive effect Effects 0.000 claims abstract description 5
- 239000000654 additive Substances 0.000 claims description 10
- 238000003860 storage Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 4
- 239000004129 EU approved improving agent Substances 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 239000011888 foil Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 238000010276 construction Methods 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 239000003623 enhancer Substances 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 5
- -1 polyoxyethylene Polymers 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- LHXDLQBQYFFVNW-XCBNKYQSSA-N (+)-fenchone Chemical compound C1C[C@]2(C)C(=O)C(C)(C)[C@H]1C2 LHXDLQBQYFFVNW-XCBNKYQSSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 2
- NIQCNGHVCWTJSM-UHFFFAOYSA-N Dimethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(=O)OC NIQCNGHVCWTJSM-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960005150 glycerol Drugs 0.000 description 2
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- OQILCOQZDHPEAZ-UHFFFAOYSA-N octyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 2
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N palmityl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 2
- 229960002622 triacetin Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- 229930006731 (1S,4R)-fenchone Natural products 0.000 description 1
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 1
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- CKNOIIXFUKKRIC-HZJYTTRNSA-N (9z,12z)-n,n-bis(2-hydroxyethyl)octadeca-9,12-dienamide Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)N(CCO)CCO CKNOIIXFUKKRIC-HZJYTTRNSA-N 0.000 description 1
- LPMBTLLQQJBUOO-KTKRTIGZSA-N (z)-n,n-bis(2-hydroxyethyl)octadec-9-enamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)N(CCO)CCO LPMBTLLQQJBUOO-KTKRTIGZSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- JSOVGYMVTPPEND-UHFFFAOYSA-N 16-methylheptadecyl 2,2-dimethylpropanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)C(C)(C)C JSOVGYMVTPPEND-UHFFFAOYSA-N 0.000 description 1
- XFOQWQKDSMIPHT-UHFFFAOYSA-N 2,3-dichloro-6-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Cl)C(Cl)=N1 XFOQWQKDSMIPHT-UHFFFAOYSA-N 0.000 description 1
- FUWVMBCPMRAWPG-UHFFFAOYSA-N 2,3-dihydroxypropyl 2-hydroxyoctadecanoate Chemical compound CCCCCCCCCCCCCCCCC(O)C(=O)OCC(O)CO FUWVMBCPMRAWPG-UHFFFAOYSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- ODMZDMMTKHXXKA-QXMHVHEDSA-N 8-methylnonyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCCCCCCC(C)C ODMZDMMTKHXXKA-QXMHVHEDSA-N 0.000 description 1
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229920004939 Cariflex™ Polymers 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical class OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- ZDQWESQEGGJUCH-UHFFFAOYSA-N Diisopropyl adipate Chemical compound CC(C)OC(=O)CCCCC(=O)OC(C)C ZDQWESQEGGJUCH-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 239000013032 Hydrocarbon resin Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- AOMUHOFOVNGZAN-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)dodecanamide Chemical compound CCCCCCCCCCCC(=O)N(CCO)CCO AOMUHOFOVNGZAN-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- JJTINRHMMASSFD-WAJSLEGFSA-N [Pb].[C@@H]12CCC(O)[C@@]1(C)CC[C@@H]1C3=C(CC[C@@H]21)C=C(O)C=C3 Chemical compound [Pb].[C@@H]12CCC(O)[C@@]1(C)CC[C@@H]1C3=C(CC[C@@H]21)C=C(O)C=C3 JJTINRHMMASSFD-WAJSLEGFSA-N 0.000 description 1
- 150000001278 adipic acid derivatives Chemical class 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- LHXDLQBQYFFVNW-UHFFFAOYSA-N alpha-fenchone Natural products C1CC2(C)C(=O)C(C)(C)C1C2 LHXDLQBQYFFVNW-UHFFFAOYSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- OPVLOHUACNWTQT-UHFFFAOYSA-N azane;2-dodecoxyethyl hydrogen sulfate Chemical compound N.CCCCCCCCCCCCOCCOS(O)(=O)=O OPVLOHUACNWTQT-UHFFFAOYSA-N 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- ZFMQKOWCDKKBIF-UHFFFAOYSA-N bis(3,5-difluorophenyl)phosphane Chemical compound FC1=CC(F)=CC(PC=2C=C(F)C=C(F)C=2)=C1 ZFMQKOWCDKKBIF-UHFFFAOYSA-N 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 229930007050 cineol Natural products 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- OTGAHJPFNKQGAE-UHFFFAOYSA-N cresatin Chemical compound CC(=O)OC1=CC=CC(C)=C1 OTGAHJPFNKQGAE-UHFFFAOYSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229960002380 dibutyl phthalate Drugs 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- FBSAITBEAPNWJG-UHFFFAOYSA-N dimethyl phthalate Natural products CC(=O)OC1=CC=CC=C1OC(C)=O FBSAITBEAPNWJG-UHFFFAOYSA-N 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 229960001826 dimethylphthalate Drugs 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- SMVRDGHCVNAOIN-UHFFFAOYSA-L disodium;1-dodecoxydodecane;sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O.CCCCCCCCCCCCOCCCCCCCCCCCC SMVRDGHCVNAOIN-UHFFFAOYSA-L 0.000 description 1
- JMGZBMRVDHKMKB-UHFFFAOYSA-L disodium;2-sulfobutanedioate Chemical class [Na+].[Na+].OS(=O)(=O)C(C([O-])=O)CC([O-])=O JMGZBMRVDHKMKB-UHFFFAOYSA-L 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 229940116333 ethyl lactate Drugs 0.000 description 1
- FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 description 1
- 229940031016 ethyl linoleate Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940043259 farnesol Drugs 0.000 description 1
- 229930002886 farnesol Natural products 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 229940100608 glycol distearate Drugs 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 229920006270 hydrocarbon resin Polymers 0.000 description 1
- 229940037626 isobutyl stearate Drugs 0.000 description 1
- 229940078545 isocetyl stearate Drugs 0.000 description 1
- 229940089456 isopropyl stearate Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940031957 lauric acid diethanolamide Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- CPXCDEMFNPKOEF-UHFFFAOYSA-N methyl 3-methylbenzoate Chemical compound COC(=O)C1=CC=CC(C)=C1 CPXCDEMFNPKOEF-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- XGZOMURMPLSSKQ-UHFFFAOYSA-N n,n-bis(2-hydroxyethyl)octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)N(CCO)CCO XGZOMURMPLSSKQ-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical class CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 description 1
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- IIGMITQLXAGZTL-UHFFFAOYSA-N octyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCC IIGMITQLXAGZTL-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- BARWIPMJPCRCTP-UHFFFAOYSA-N oleic acid oleyl ester Natural products CCCCCCCCC=CCCCCCCCCOC(=O)CCCCCCCC=CCCCCCCCC BARWIPMJPCRCTP-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000005011 phenolic resin Substances 0.000 description 1
- 229920001568 phenolic resin Polymers 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003021 phthalic acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920006267 polyester film Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000223 polyglycerol Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 description 1
- 150000003097 polyterpenes Chemical class 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940114930 potassium stearate Drugs 0.000 description 1
- ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- ZPWFUIUNWDIYCJ-UHFFFAOYSA-N propan-2-yl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C ZPWFUIUNWDIYCJ-UHFFFAOYSA-N 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- LIVNPJMFVYWSIS-UHFFFAOYSA-N silicon monoxide Chemical class [Si-]#[O+] LIVNPJMFVYWSIS-UHFFFAOYSA-N 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229960005480 sodium caprylate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- BORJONZPSTVSFP-UHFFFAOYSA-N tetradecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)C(C)O BORJONZPSTVSFP-UHFFFAOYSA-N 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Description
Denne oppfinnelse vedrører et transdermalt terapeutisk system for frigjøring av 17-Ii-østradiol og eventuelt ytterli--gere virkestoffer gjennom huden på det menneskelige legemet.
Transdermale terapeutiske systemer (TTS) er allerede innført i markedet for legemiddelterapien av en rekke sykdom-mer. Også TTS med virkestoffet 17-Ii-østradiol har i mellomti-den oppnådd gode resultater i handelen og i terapien som terapeutikum for klimakteriumplager, i senere tid også mot osteoporose. Systemene beskrevet i EP 0 421 454 inneholder østradiol i en vannsvellbar akrylatpolymer under tilsetning av "krystallisasjonshemmere" og klebriggjørende harpikser. Påvirkningen av løseligheten av østradiol gjennom forskjellig vanndamptrykk ble imidlertid ikke erkjent, og følgelig finnes det heller ikke noen resept for den korrekte innstilling av konsentrasjonen av østradiol.
En ulempe ved de kjente systemene er nødvendigheten av å måtte anvende såkalte "enhancere". Det dreier seg her i regelen om flytende tilsetningsstoffer som forbedrer resorp-sjonsegenskapene til den menneskelige hud, og dermed også muliggjør opptaket av virkestoffet østradiol fra en tilstrekkelig liten TTS-flate. Særlig de lett flyktige enhancere som den i tilfellet østradiol regelmessig anvendte etanol fører til problemer med> den altfor sterke oppmykning av klebesjikt-ene i TTS, og gjør det fremfor alt nødvendig med ytterligere plasskrevende rom i systemet, hvilket fører til at TTS får uakseptabelt store flater, hhv. uakseptabel tykkelse.
Under tilsetning av bestemte mindre flyktige, for det meste også mindre aktive enhancere er det allikevel mulig å fremstille matrikssystemer som inneholder virkestoffet og de resorpsjonsforsterkende komponenter i ett eller noen få mono-littiske sjikt. US 4.863.738 er således et eksempel blant flere, hvori det gjøres krav på påføring av virkestoffer, f.eks. østradiol sammen med en bestemt enhancer (her glycerolmonooleat) i en vilkårlig TTS-matriks i vilkårlig konsentra-sjon. Imidlertid er det ifølge teknikkens stand heller ikke med slike TTS mulig å oppnå noen tilfredsstillende terapi, da enten de utvalgte enhancere er for dårlig forlikelige med huden eller TTS-systemene pga. den fremdeles altfor svake strømning gjennom huden må ha uakseptabelt store flater. Et ytterligere problem er det faktum at tallrike reseptur-varianter av slike systemer har tendens til omkrystallisering av tilsynelatende uforutsigbare årsaker, og derved taper en stor del av sin terapeutiske aktivitet.
Konsentrasjonsangivelser tilsvarende teknikkens stand finnes f.eks. i GB 2 138 286 (mellom 0,01% østradiol og met-ningsløseligheten i løsningsmidlet), i EP 0 421 454 (0,5% til 10% i polymeren) eller i BE 899 444 (mellom 20% og metning).
Følgelig er det oppgaven for denne oppfinnelse å tilvei-ebringe et akseptabelt tynt og med hensyn til flaten lite TTS, som ikke inneholder noen lettflyktige enhancere, i løpet av lagringstiden ikke lider noen aktivtetstap ved omkrystallisering og allikevel har en høy strømningshastighet med hensyn på flaten (mg/cm<2>/time) på huden.
Denne oppgave løses ifølge oppfinnelsen ved et transdermalt terapeutisk system, inneholdende virkestoffet 17-15-østradiol og eventuelt ytterligere'virkestoffer, med sjiktvis oppbygging av et i alt vesentlig fuktighetsugjennomtrengelig baksjikt, ett eller flere matrikssjikt og eventuelt et klebesjikt, ved at konsentrasjonen av den løste østradiol i alle matrikssjikt og eventuelt i klebesjiktet ligger mellom sin metningskonsentrasjon i tørr tilstand og sin metnings-konsentras j on i fuktig tilstand, hvorved med begrepet "tørr tilstand" skal forstås at grunnmaterialet står i likevekt med en gassfase med mindre enn 10% relativ luftfuktighet og med begrepet "fuktig tilstand" at grunnmaterialet står i likevekt med en gassfase med mer enn 90% relativ luftfuktighet.
Ytterligere verdifulle egenskaper for det transdermale terapeutiske system gir seg gjennom dettes utforming tilsvarende underkravene, hvorved det i løpet av lagringen fordelaktig har en likevektsfuktighet inntil 40% relativ luftfuktighet. Derved har overraskende alle matrikssjikt og ved tilstedeværelse av et klebesjikt også dette i fuktighetslikevekt med inntil 10% relativ luftfuktighet en minst 50% høyere løselig-het for virkestoffet 17-li-østradiol, enn i fuktighetslikevekt med minst 90% relativ luftfuktighet. Det er fordelaktig når - alle matrikssjikt og ved tilstedeværelse av et klebesjikt at disse består av en akrylsyreesterkopolymer med en løselighet for virkestoffet 17-Ii-østradiol mellom 0,2 og 2,0 (g/g), bestemt i fuktighetslikevekt med 10% relativ luftfuktighet. Hensiktsmessig vil ett eller flere av matrikssjiktene eller ved tilstedeværelse av et klebesjikt også dette inneholde ett eller flere stoffer fra gruppen av klebemidler, hudgjennomtrengningsforbedrende tilsetninger, fyllstoffer, løselighets-forbedringsmidler eller tilsetningsstoffer svellbare i vann.-Derved kan det alltid i ett eller flere sjikt av matriksen og/eller i et klebesjikt inneholdes følgende komponenter: Som bestanddel av hefteklebmidlet klebriggjørende harpikser som kolofonium og dets derivater, polyterpenharpikser fra a- eller ft-pinen, alifatiske, aromatiske eller alkylaromatiske hydrokarbonharpikser, melamin-formaldehyd-harpikser, fenol-harpikser, hydroabietylalkohol og deres blandinger.
Som fyllstoffer karbonater, fosfater, silikater, sulfater og oksyder av jordalkalimetallene, sinkoksyd, silisiumoksyder, cellulose og dens derivater, talkum eller titandioksyd, men også tungtløselige sukker (-derivater), som f.eks. laktose eller stivelsesderivater som cyklodekstrin.
Som løselighetsforbedrende tilsetninger hhv. hudgjennom-trengningsforbedringsmidler acetylaceton, acetyltributyl-citrat, acetyltrietylcitrat, avokadoolje, bomullsfrøolje, benzylalkohol, butylstearat, cetyllaktat, cetylpalmitat, cetylstearat, cetylstearylalkohol/cetylalkohol, klorbutanol, cineol, decylmetylsulfoksyd, decyloleat, dibutylftalat, di-etylenglykolmonoetyleter, dietylftalat, dietylsebacat, di-isopropyladipat, dimetylftalat, dimetylsulfoksyd, dioktyl-adipat, dipropylenglykol, glycerolmonooleat, glycerolmono-stearat, stearylalkohol, jordnøttolje, etyllaktat, etyl-linolat, etyl-(9,12,15)-linolenat, eugenol, farnesol, gly-cerol, glycerolacetylester, glycerolstearat, glykoldistearat, glyoksal, heksadekanol, heksylenglykol, vaselin, petrolatum, isobutylstearat, isocetylstearat, isodecyloleat, isopropyl-lanolat, isopropylmyristat/isopropylpalmitat, isopropyl-stearat, isostearylneopentanoat, laurinsyredietanolamid, limonen, linolensyre, linolsyredietanolamid, mandelolje, mentol, myntolje, myristyllaktat, myristylmyristat, myristyl-stearat, m-tolylacetat, nellikolje, oktyldodekanol, oktyl-palmitat, oktylstearat, oljesyredietanolamid, oleylalkohol, oleyloleat, olivenolje, parafin, flytende = mineralolje, petroleum, peppermintolje, fenyletylalkohol, isostearinsyre, oktansyre, propylenkarbonat, propylenglykol, rizinusolje/- hydrert/raffinert, saflorolje, squalan, squalen, triacetin, glyceroltriacetat, trietylcitrat, undecylensyre, propylenglykol, propandiol, 1,3-butylenglykol, (+)-fenchon, ammonium-lauryletersulfat, kolsyre, kolesterol, kaliumstearat, lecitin, glycerolhydroksystearat, mono- og diglycerid av spisefett-syrer, natriumkaprylat, natriumlauryletersulfat, Na-/K-salter av spisefettsyrene, Na-laurylsulfat, PEG-(2)-stearat, natrium-sulfosuccinat, polyglycerolestere av spisefettsyrene, poly-oksyetylenalkyleter, cetomakrogol, polyoksyetylenfettsyre-sorbitanester, propylenglykolstearat, sorbitanfettsyreester, stearinsyredietanolamid.
Som i vann svellbare tilsetninger som stivelse og dens derivater, agar-agar, alginsyre, arabinogalaktan, galakto-mannan, cellulose og dens derivater, karragen, dekstran, traganth og flere andre gummityper av planteopprinnelse, samt i vann løselige eller svellbare, syntetiske polymerer som polyvinylpyrrolidon, polyvinylalkohol, polyakrylsyre eller polyakrylamid, for bare å nevne noen. Polypeptider som gela-tin, albumin, kollagen eller eggehvite.
Som krystallisasjonshemmere ftalsyreestere, adipinsyre-estere, mono-, di- og triglyceridér, estere av høyere fettsyrer, langkjedede alkoholer og deres derivater, derivater av nonylfenol hhv. av oktylfenol, derivater av fettsyrer, derivater av sorbit og av mannit, ikke-ionogene tensider, polyoksy-etylenalkyletere, derivater av rizinusoljen, sitosterin og polyvinylpyrrolidon, samt ytterligere stoffer kjent for fagmannen.
Prinsippet ifølge oppfinnelsen opptrer på sammenlignbar måte også ved andre grunnmaterialer for transdermale terapeutiske systemer. Hertil er fremfor alt den korrekte innstil- - ling av østradiol-konsentrasjonen viktig. Denne må være høyere enn metningskonsentrasjonen i fuktig tilstand, men lavere enn metningskonsentrasjonen under tørre betingelser. Til fremstilling av systemer ifølge oppfinnelsen er det også nødvendig på forhånd å utføre eksperimentelle løselighets-bestemmelser. Da polymerenes vannopptaksevne er høyst forskjellig og også temperaturavhengig, ville en beskrivelse av tilstandene "fuktig" og "tørr" ved absolutte konsentrasjonsangivelser av vann i grunnmaterialet ikke beskrive forholdene presist nok. Det er snarere nødvendig å ta til hjelp det i farmasien vanlige begrep ekvivalentfuktighet. Dermed betegnes den fuktighet som et materiale antar i likevekt med en på forhånd innstilt relativ luftfuktighet i omgivelsene. Hensiktsmessig gjennomføres østradiolløselighetsbestemmelsen derfor i såkalte hygrostater, hvori et hjelpemateriale med kjent ekvivalentfuktighet (saltløsninger, silikagel, fosfor-pentoksyd osv.) blir lagret sammen med prøven i en innelukket beholder over en viss tid (dager til uker).
I vedlagte eksempel 1 ble det anvendt praksisnære varian-ter av slike hygrostater, og med deres hjelp ble det anvendt ekvivalentfuktigheter fra ca. 0 til 1%, men sikkert under 10% relativ luftfuktighet - tørr tilstand - (silikagel) hhv. ca. 97 - 98% - fuktig tilstand - (såkalt fysiologisk koksalt-løsning).
Den metode for løselighetsbestemmelse som anvendes ved disse forsøk må tilpasses av fagmannen til det aktuelle problem. En enkel mulighet er den som er beskrevet i eksempel 1.
Her ble det laget testformuleringer med forskjellige høye virkestoffinnhold og lagret under fuktighetskontrollerte betingelser. Deretter ble det enten visuelt eller mikro-skopisk bestemt om virkestoffet nu foreligger fullstendig løst eller tvert i mot utfelt.
Ekvivalentfuktighet under 40% relativ luftfuktighet fordelaktig for fremstillings- og lagringsfremgangsmåten, kan foruten ved anvendelse av hygrostat-prinsippet også enkelt oppnås ved tilstrekkelig avskjerming (forpakning) av godset fra den omgivende luft.
En fremgangsmåte til fremstilling av TTS ifølge oppfinnelsen er forutsett tilsvarende bemerkningene i kravene 6 til 8.
Eksempel 1:
Til bestemmelse av påvirkningen av løseligheten av 17 —li — østradiol ved forskjellig lagringsfuktighet ble det først trukket frem følgende virkestoffholdige klebrige sjikt (sjikttykkelse tilsvarende ca. 60 um) :
Sjiktene ble for beskyttelse av overflatene kasjert luftboblefritt mellom en 15 um tykk PETP-membran og et objekt-glass (76 x 26 mm).
Prøvene ble forseglet sammen med den nødvendige fuktig-hetsregulerende innretning (se nedenfor) i forseglbart inn-pakningsmateriale (papir/aluminium/etylenvinylacetat) og lagret ved romtemperatur i 1 år.
Fuktighetsregulatoer:
1. "Fuktig": innlagte striper av platevatt, dynket med ca.
1 ml 0,9% natriumkloridløsning i vann.
2. "Tørr": ca. 10 småkorn av blågel, ca. 1 g.
Da hver prøve A-H ble lagret under begge betingelser, fikk man 16 forskjellige prøver til observasjon.
Etter utløp av lagertiden ble prøvene undersøkt på ut-fellinger av virkestoffet. Derved ble utelukkende mikrosko-pisk feilfritt erkjennbare krystaller som opptrer på overfla-ten, ansett som "omkrystallisasjon".
Konsentrasjonsområdet, hvori prinsippet ifølge oppfinnelsen kan benyttes, ligger alstå mellom 0,6 og 1,3% østradiol (g</>g)<.>
Eksempel 2:
Fremstilling av et system ifølge oppfinnelsen:
1,0 g 17-Ii-østradiol
60,0 g Cariflex R TR 1107 (Styrol-isopren-styrol-blokkopolymer)
138,0 g Foral R 85 (termoplastisk esterharpiks) av kolofoniumderivater)
200,0 g benzin (kokeomårde 80 til 100°C)
omrøres ved romtemperatur i en sylindrisk glassbeholder inntil det oppnås en jevn suspensjon, og besjiktes deretter på et kontinuerlig arbeidende besjiktingsanlegg til 100 ym tykk, silikonisert polyesterfolie slik at det oppnås en sjikttykkelse på 100 g/m<2> (i forhold til den løsemiddelfrie andel).
Utstrykningen tørkes hver gang i 4 min. ved 40°C, 60°C, 80°C og ved 120°C. Deretter legges straks en 15 um tykk polyester-, folie luftboblefritt under valsetrykk på det tørkede sjikt (til kasjering).
Ved utstansing med Henkelhulljern oppnås transdermale systemer pa 16 cm .
Med det transdermale terapisystem ifølge oppfinnelsen oppnås følgende fordelaktige virkninger:
gode resorpsjonsegenskaper for den menneskelige hud,
god forlikelighet med huden, tilstrekkelig virkestoffstrøm gjennom huden ved aksepta-bel flate (cm<2>) av TTS,
ingen omkrystallisering av virkestoffet under lagringen.
Claims (8)
1. Transdermalt terapeutisk system inneholdende virkestoffet 17-Ii-østradiol og eventuelt ytterligere virkestoffer, med sjiktvis oppbygging av et i alt vesentlig fuktighetsugjennomtrengelig samt virkestoffugjennomtrengelig baksjikt, ett eller flere matrikssjikt og ved tilstedeværelse av ikke-klebrige matrikssjikt et klebesjikt, karakterisert ved at konsentrasjonen av den oppløste østradiol i alle matrikssjikt og ved tilstedeværelse av et klebesjikt i dette ligger mellom sin metningskonsentrasjon i tørr tilstand og sin metningskonsentrasjon i fuktig tilstand, hvorved det med begrepet "tørr tilstand" skal forstås at grunnmaterialet står i likevekt med en gassfase med mindre enn 10% relativ luftfuktighet, og med begrepet "fuktig tilstand", at grunnmaterialet står i likevekt med en gassfase med mer enn 90% relativ luftfuktighet.
2. Transdermalt terapeutisk system ifølge krav 1, karakterisert ved at det i løpet av frem-stillingen og lagringen har en likevektsfuktighet inntil 40% relativ luftfuktighet.
3. Transdermalt terapeutisk system ifølge krav 1 eller 2,
karakterisert ved at alle matrikssjikt og ved tilstedeværelse av et klebesjikt også dette i fuktighetslikevekt med inntil 10% relativ luftfuktighet har en minst 50% høyere løselighet for virkestoffet 17-Ii-østradiol enn i fuktighetslikevekt med minst 90% relativ luftfuktighet.
4. Transdermalt terapeutisk system ifølge krav 3, karakterisert ved at alle matrikssjikt og ved tilstedeværelse av et klebesjikt også dette består av en akrylsyreesterkopolymer med en løselighet for virkestoffet 17-Ii-østradiol mellom 0,2 og 2,0% (g/g), bestemt i fuktighetslikevekt med 10% relativ luftfuktighet.
5. Transdermalt terapeutisk system ifølge ett eller flere av de foregående krav,
karakterisert ved at ett eller flere matrikssjikt eller ved tilstedeværelse av et klebesjikt også dette inneholder ett eller flere stoffer fra gruppen av klebemidler, hudgjennomtrengningsforbedrende tilsetninger, fyllstoffer, løselighetsforbedringsmidler eller tilsetningsstoffer svellbare i vann.
6. Fremgangsmåte til fremstilling av det transdermale terapeutiske system ifølge kravene 1 til 5, karakterisert ved at virkestoffet ved romtemperatur blir omrørt sammen med bestanddeler av matriks-sjiktet hhv. klebejsiktet, samt med ett eller flere tilsetningsstoffer fra gruppen av klebemidler, hudgjennomtrengningsforbedrende tilsetninger, fyllstoffer, løselighets-forbedringsmidler og/eller tilsetningsstoffer svellbare i vann inntil det oppnås en jevn suspensjon og deretter blir be-sjiktet på en dehesivt utrustet folie, slik at resultatet blir en sammenligningsvis tynn sjikttykkelse, hvorpå påstrykningen blir tørket noen minutter ved trinnvis hevet temperatur, til sist ved ca. 120°C, og på det tørkede sjikt øyeblikkelig blir pålagt en dekkfolie luftboblefritt under valsetrykk og denne dermed blir tilkasjert, hvoretter det til slutt blir utstanset enkelte transdermale systemer med definert flateinnhold.
7. Fremgangsmåte ifølge krav 6,
karakterisert ved å påføre besjiktningen på den dehesivt utrustede folie med en besjiktingsmasse på ca. 100 g/m<2> i forhold til den løsningsmiddeltrie andel.
8. Fremgangsmåte ifølge krav 6 eller 7, karakterisert ved å gjennomføre tørkingen av sjiktet hver gang i ca. 4 min. ved hhv. 40°C, 60°C, 80°C og 120°C.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4237453A DE4237453C1 (no) | 1992-11-06 | 1992-11-06 | |
PCT/EP1993/002971 WO1994010984A1 (de) | 1992-11-06 | 1993-10-27 | TRANSDERMALES THERAPEUTISCHES SYSTEM ZUR ABGABE VON 17-β-ESTRADIOL UND VERFAHREN ZU SEINER HERSTELLUNG |
Publications (3)
Publication Number | Publication Date |
---|---|
NO951765L NO951765L (no) | 1995-05-05 |
NO951765D0 NO951765D0 (no) | 1995-05-05 |
NO311783B1 true NO311783B1 (no) | 2002-01-28 |
Family
ID=6472230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19951765A NO311783B1 (no) | 1992-11-06 | 1995-05-05 | Transdermalt terapeutisk system for frigjöring av 17-<beta>- östradiol og fremgangsmåte for fremstilling derav |
Country Status (24)
Country | Link |
---|---|
US (1) | US5912008A (no) |
EP (1) | EP0716599B1 (no) |
JP (1) | JP3237016B2 (no) |
KR (1) | KR100306946B1 (no) |
AT (1) | ATE164516T1 (no) |
AU (1) | AU678408B2 (no) |
CA (1) | CA2147172C (no) |
CZ (1) | CZ286907B6 (no) |
DE (2) | DE4237453C1 (no) |
DK (1) | DK0716599T3 (no) |
ES (1) | ES2117152T3 (no) |
FI (1) | FI113339B (no) |
HR (1) | HRP931360B1 (no) |
HU (1) | HU221847B1 (no) |
IL (1) | IL107395A (no) |
MY (1) | MY118171A (no) |
NO (1) | NO311783B1 (no) |
NZ (1) | NZ257137A (no) |
PL (1) | PL174604B1 (no) |
SI (1) | SI9300581A (no) |
SK (1) | SK279911B6 (no) |
WO (1) | WO1994010984A1 (no) |
YU (1) | YU69693A (no) |
ZA (1) | ZA938257B (no) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE95059T1 (de) * | 1989-02-28 | 1993-10-15 | Teijin Ltd | Pflaster sowie dessen herstellung. |
EP0695177B1 (de) * | 1993-04-20 | 1998-02-18 | Hexal Ag | Wirkstoffplaster |
DE4429664C2 (de) * | 1994-08-20 | 1997-09-11 | Lohmann Therapie Syst Lts | Estradiol-TTS mit wasserbindenden Zusätzen und Verfahren zu seiner Herstellung |
US5906830A (en) * | 1995-09-08 | 1999-05-25 | Cygnus, Inc. | Supersaturated transdermal drug delivery systems, and methods for manufacturing the same |
DE19600347A1 (de) * | 1996-01-08 | 1997-07-10 | Lohmann Therapie Syst Lts | Hauthaftende pharmazeutische Zubereitung, insbesondere TTS zur Abgabe von 17-beta-Estradiol an den menschlichen Organismus |
DE19701949A1 (de) * | 1997-01-13 | 1998-07-16 | Jenapharm Gmbh | Transdermales therapeutisches System |
US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
DE19827732A1 (de) * | 1998-06-22 | 1999-12-23 | Rottapharm Bv | Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie |
JP4399044B2 (ja) * | 1998-10-14 | 2010-01-13 | 久光製薬株式会社 | 吸収促進剤及び該吸収促進剤を有してなる経皮吸収製剤 |
US6631186B1 (en) * | 1999-04-09 | 2003-10-07 | Sbc Technology Resources, Inc. | System and method for implementing and accessing call forwarding services |
DE19925613A1 (de) | 1999-06-04 | 2000-12-07 | Lohmann Therapie Syst Lts | Verbundlaminat und Verfahren zu seiner Herstellung |
ITRM20060440A1 (it) * | 2006-08-10 | 2008-02-11 | Carmine Antropoli | Uso della nifedipina per il trattamento antirughe |
US20100087768A1 (en) * | 2008-10-02 | 2010-04-08 | Forlano Paula | Transdermal drug delivery system for liquid active ingredient |
DE102010026903A1 (de) | 2010-07-12 | 2012-01-12 | Amw Gmbh | Transdermales therapeutisches System mit Avocadoöl oder Palmöl als Hilfsstoff |
WO2013006613A1 (en) | 2011-07-05 | 2013-01-10 | Novan, Inc. | Methods of manufacturing topical compositions and apparatus for same |
WO2013006608A1 (en) | 2011-07-05 | 2013-01-10 | Novan, Inc. | Topical compositions |
DE102012000369A1 (de) | 2012-01-11 | 2013-07-11 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermales therapeutisches System mit Cholinesterase-Hemmer |
US9855211B2 (en) | 2013-02-28 | 2018-01-02 | Novan, Inc. | Topical compositions and methods of using the same |
KR102495101B1 (ko) | 2014-07-11 | 2023-02-02 | 노반, 인크. | 국소 항바이러스 조성물 및 그의 사용 방법 |
US10322082B2 (en) | 2014-07-11 | 2019-06-18 | Novan, Inc. | Topical antiviral compositions and methods of using the same |
EP3442502A4 (en) | 2016-04-13 | 2019-11-06 | Novan, Inc. | COMPOSITIONS, SYSTEMS, KITS AND METHODS FOR TREATING INFECTION |
DE102017127433A1 (de) | 2017-11-21 | 2019-05-23 | Lts Lohmann Therapie-Systeme Ag | TTS auf Basis von klebenden Weichmacher-Polymer-Matrices |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR527450A (fr) * | 1919-12-04 | 1921-10-25 | Gilbert Mahaut | Système et dispositif pour la combustion des huiles lourdes dans les foyers industriels et autres |
US4435180A (en) * | 1982-05-25 | 1984-03-06 | Alza Corporation | Elastomeric active agent delivery system and method of use |
GB2138286B (en) * | 1983-04-19 | 1986-10-08 | Dr Christopher Harry Mortimer | Pharmaceutical composition for the treatment of hair loss |
DE3587616D1 (de) * | 1984-12-22 | 1993-11-11 | Sanol Arznei Schwarz Gmbh | Wirkstoffpflaster. |
US5145682A (en) * | 1986-05-30 | 1992-09-08 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for postmenopausal syndrome treatment and process for administration |
US5023084A (en) * | 1986-12-29 | 1991-06-11 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
FR2612785A1 (fr) * | 1987-03-25 | 1988-09-30 | Lhd Lab Hygiene Dietetique | Dispositif auto-adhesif d'administration d'un principe actif par voie percutanee |
US4863738A (en) * | 1987-11-23 | 1989-09-05 | Alza Corporation | Skin permeation enhancer compositions using glycerol monooleate |
US4994267A (en) * | 1988-03-04 | 1991-02-19 | Noven Pharmaceuticals, Inc. | Transdermal acrylic multipolymer drug delivery system |
ATE95059T1 (de) * | 1989-02-28 | 1993-10-15 | Teijin Ltd | Pflaster sowie dessen herstellung. |
DE3933460A1 (de) * | 1989-10-06 | 1991-04-18 | Lohmann Therapie Syst Lts | Oestrogenhaltiges wirkstoffpflaster |
AU6712090A (en) * | 1989-10-13 | 1991-05-16 | Watson Laboratories, Inc. | Drug delivery systems and matrix therefor |
AR246186A1 (es) * | 1989-11-17 | 1994-07-29 | Beta Pharm Co | Procedimiento para fabricar un dispositivo para administrar estradiol por via transdermica. |
DE4002281A1 (de) * | 1990-01-26 | 1991-08-01 | Lohmann Therapie Syst Lts | Transdermales therapeutisches system mit dem wirkstoff tulobuterol |
DE69108512T2 (de) * | 1990-05-17 | 1995-08-03 | Hisamitsu Pharmaceutical Co | Estradiol enthaltende transdermale zubereitung. |
-
1992
- 1992-11-06 DE DE4237453A patent/DE4237453C1/de not_active Revoked
-
1993
- 1993-10-21 MY MYPI93002178A patent/MY118171A/en unknown
- 1993-10-25 IL IL10739593A patent/IL107395A/xx not_active IP Right Cessation
- 1993-10-27 JP JP51165094A patent/JP3237016B2/ja not_active Expired - Lifetime
- 1993-10-27 SK SK580-95A patent/SK279911B6/sk not_active IP Right Cessation
- 1993-10-27 ES ES93923559T patent/ES2117152T3/es not_active Expired - Lifetime
- 1993-10-27 AT AT93923559T patent/ATE164516T1/de active
- 1993-10-27 CA CA002147172A patent/CA2147172C/en not_active Expired - Lifetime
- 1993-10-27 WO PCT/EP1993/002971 patent/WO1994010984A1/de active IP Right Grant
- 1993-10-27 NZ NZ257137A patent/NZ257137A/en not_active IP Right Cessation
- 1993-10-27 DK DK93923559T patent/DK0716599T3/da active
- 1993-10-27 AU AU53386/94A patent/AU678408B2/en not_active Expired
- 1993-10-27 KR KR1019950701791A patent/KR100306946B1/ko not_active IP Right Cessation
- 1993-10-27 DE DE59308360T patent/DE59308360D1/de not_active Expired - Lifetime
- 1993-10-27 HU HU9501318A patent/HU221847B1/hu active IP Right Grant
- 1993-10-27 EP EP93923559A patent/EP0716599B1/de not_active Expired - Lifetime
- 1993-10-27 PL PL93308532A patent/PL174604B1/pl unknown
- 1993-10-27 CZ CZ19951162A patent/CZ286907B6/cs not_active IP Right Cessation
- 1993-11-03 YU YU69693A patent/YU69693A/sh unknown
- 1993-11-04 HR HRP4237453.7A patent/HRP931360B1/xx not_active IP Right Cessation
- 1993-11-05 SI SI9300581A patent/SI9300581A/sl unknown
- 1993-11-05 ZA ZA938257A patent/ZA938257B/xx unknown
-
1995
- 1995-05-03 FI FI952115A patent/FI113339B/fi not_active IP Right Cessation
- 1995-05-05 NO NO19951765A patent/NO311783B1/no not_active IP Right Cessation
-
1997
- 1997-06-16 US US08/876,427 patent/US5912008A/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO311783B1 (no) | Transdermalt terapeutisk system for frigjöring av 17-<beta>- östradiol og fremgangsmåte for fremstilling derav | |
KR950015058B1 (ko) | 활성 성분으로 피소스티그민을 함유하는 경피 치료 시스템 및 그 제조방법 | |
EP0608357B1 (en) | Device for administering drug transdermally with a controlled temporal change in skin flux | |
US5352457A (en) | Transdermal device | |
NO180108B (no) | Fremgangsmåte ved fremstilling av et transdermalt system med virkestoffet Tulobuterol | |
JP2003501294A (ja) | コンポジットラミネートおよびその製法 | |
JP2016522792A (ja) | リバスチグミンを含む、経皮薬物送達システム | |
JP3227577B2 (ja) | 活性物質,17−β−エストラジオール(無水)を含有する経皮医療システム | |
KR100473677B1 (ko) | 물리적 특성이 향상된 폴리아크릴레이트 매트릭스를 구비한 경피 또는 국소 플래스터 시스템 | |
US5989585A (en) | Transdermal therapeutic system (TTS) containing vitamin E for the treatment of drug dependency | |
EP0290262A2 (en) | Improved nitrate therapy for angina pectoris | |
AU725245B2 (en) | Extensible transdermal therapeutic system | |
US6733785B1 (en) | Moisture-sensitive preparation of percutaneous absorption type | |
RU2108812C1 (ru) | Трансдермальная терапевтическая система и способ ее получения | |
KR0143549B1 (ko) | pH-조절된 조건하 약리학적 화합물 투여용 개선된 경피 전달장치 | |
US5827245A (en) | Transdermal therapeutic system comprising the active subtance 17-β-Estradiol (Anhydrous) | |
KR19990077110A (ko) | 17-β-에스트라디올을 인체로 방출하기 위한 피부 접착용 약제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1K | Patent expired |